Document is current

Article History

Received: 3 March 2023

Accepted: 24 October 2023

First Online: 11 November 2023

Competing interests

: S.M.L. has received research grants from Yuhan and Janssen; received consulting fees from AstraZeneca, Boehringer Ingelheim, Lilly, Takeda, Guardant and J Ints Bio; and received research grants from AstraZeneca, Beigene, Boehringer Ingelheim, GSK, Roche, Hengrui, BridgeBio Therapeutics, Oscotec, and Daichii-Sankyo. S.P. has an advisory role with AbbVie, AiCME, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Peerview, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, and Vaccibody; has been an invited speaker for AiCME, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Foundation Medicine, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Mirati, Novartis, PER, Peerview, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, and Takeda; and received research grants from Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, and Roche/Genentech. A.L.O.G. is an employee of the Servicio Andaluz de Salud and has had an advisory role for Roche, Bristol Myers Squibb, and Merck Sharp Dohme. GdJP has no conflicts of interest to disclose. C.S.F. has been an invited speaker for Fundacion Respirar. G.L.R. has received consulting fees from Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, Amgen, Sanofi, Italfarmaco and Pfizer; received honoraria from Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, Amgen, and Sanofi; received travel grants from Roche, BMS, and MSD; had an advisory role for Roche, Novartis, BMS, MSD, AstraZeneca, and Sanofi; and been an investigator for clinical trials sponsored by Roche, Novartis, BMS, MSD, AstraZeneca, GSK, Amgen, and Sanofi. MS has had contracts for clinical trial activities (institutional and personal as site Principal Investigator) with GSK, Merck Serono, BMS, MSD, Roche, Sanofi, Regeneron, Astellas, Amgen, Bayer, BeiGene, Clovis, Tesaro, Gilead, Bioven, Novartis, Pfizer, Eli Lilly, Pharma Mar, AbbVie, Astra Zeneca, Mylan, and Daiichi Sankyo. JSA has been an invited speaker for Kyowa Kirin, Amgen Korea, Yuhan, AstraZeneca Korea, Menarini Korea, Bayer Korea, Takeda Phar, Novartis Korea, Hanmi, BC World, Pfizer, Roche Korea, and Boehringer Ingelheim; and had an advisory role for Yuhan, Bayer Korea, Yooyoung, Pharmbio Korea, Vifor Pharma, and Bixink. MR has had an advisory role for Amgen, AstraZeneca, Beigene, BMS, Boehringer Ingelheim, Daiichi-Sankyo, GSK, Lilly, Merck, MSD, Novartis, Pfizer, Regeneron, Roche, Samsun Bioepsis, and Sanofi. Z.S. is an employee of GSK. N.H. is a former employee of GSK (at time of study) and is a current employee of Lantheus Medical Imaging. E.Z. is an employee of GSK. E.B. is an employee of GSK and holds stocks/shares in GSK. N.S. is an employee of GSK and their spouse works for Debiopharm. S.O’.D. is an employee of GSK and their spouse works as a federal employee. F.d.M. has had an advisory role for AstraZeneca, Roche, Novartis, Merck, BMS, and MSD.